Link Archives - Page 3 of 13 - Corcept Therapeutics

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

March 26, 2023

Alexander Olawaiye et al. • 2023 • SGO Annual Meeting 2023

Phase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

February 16, 2023

Michael Morris et al. • 2023 • ASCO GU Cancers Symposium 2023

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

February 15, 2023

Pivonello et al • 2022 • Front. Endocrinol.

Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab

February 13, 2023

Colombo et al • 2022 • International Gynecologic Cancer Society 2022 Annual Meeting

Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel

February 12, 2023

Lorusso et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

February 11, 2023

Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study

February 10, 2023

Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

February 9, 2023

Munster et al • 2022 • Clin Cancer Res OF1–OF11

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing Syndrome

February 8, 2023

Moraitis et al • 2022 • ENDO 2022 Annual Meeting

Impact of mifepristone on liver function and liver steatosis in patients with Cushing Syndrome

February 7, 2023

East et al • 2022 • ENDO 2022 Annual Meeting

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices